



(51) International Patent Classification:

A61K 39/395 (2006.01) G01N 33/574 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/SG2020/050044

(22) International Filing Date:

30 January 2020 (30.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10201900943X 31 January 2019 (31.01.2019) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG).


(72) Inventors: **BARD, Frederic**; c/o Institute of Molecular and Cell Biology (IMCB), 61 Biopolis Drive, Proteos, Singapore 138673 (SG). **NGUYEN, Anh Tuan**; c/o Institute of Molecular and Cell Biology (IMCB), 61 Biopolis Drive, Proteos, Singapore 138673 (SG). **MANON, Ros**; c/o Institute of Molecular and Cell Biology (IMCB), 61 Biopolis Drive, Proteos, Singapore 138673 (SG).

(74) Agent: **KHOO, Chong-Yee**; Cantab IP Pte Ltd, VBox 881846, Singapore 919191 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: CNX/ERP57 INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CANCER

FIGURE 5C



(57) Abstract: The present invention relates to a Calnexin (Cnx) / Protein Disulfide Isomerase (PDI) ERp57 inhibitor for use in the treatment or prevention of cancer. In particular, the cancer comprises invasive or metastatic cancer, or is characterised by elevated levels of O-glycosylation. The present invention also relates to a method of (a) detecting a cancer cell; (b) determining the likelihood that a cell will become invasive or aggressive; or (c) predicting a decreased survival rate of an individual with cancer, the method comprising detecting increased expression, amount or activity of Cnx/ERp57 in the cell, or a cell of the individual, as compared to a non-cancerous cell. In addition, also disclosed are a method of choosing a therapy for an individual with cancer and a method of determining the likelihood of success of a particular therapy in an individual with cancer, the methods comprising detecting modulation of expression of Cnx/ERp57 in a cell of the individual.

[Continued on next page]

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*